The pivotal relation between glucagon-like peptides, NFκB and inflammatory bowel disease.

Clinical and Experimental Pharmacology & Physiology
Omnia Azmy NabehNawal El-Sayed El-Gawhary

Abstract

Glucagon-like peptides (GLPs), GLP-1 and GLP-2, are released from intestinal enteroendocrine cells (L cells) in response to ingested nutrients. GLP-1 plays a crucial role in lowering blood glucose and controlling body weight, through stimulating the islet ß cells of pancreas to secrete insulin, inhibiting gastric emptying, and reducing food ingestion. Therefore, GLP-1 receptor agonists are now used in the treatment of obese patients with type 2 diabetes mellitus (T2DM). GLP-2, on the other hand, is used as a novel therapy for short bowel syndrome (SBS) through its ability to restore intestinal homeostasis and induce epithelial proliferation. GLPs and the inhibitors of their degradation enzymes, dipeptidyl peptidase-IV (DPP-IV) inhibitors, have many anti-inflammatory actions. Many animal-based clinical trials have proved that GLP-based therapy has a pivotal role in the management of inflammatory bowel disease (IBD), possibly through regulating the transcription factor nuclear factor kappa-ligand B (NFκB). NFκB controls the production and secretion of many cytokines and chemokines encountered in the pathophysiology of IBD such as interleukin (IL-1β-IL-12, IL-13, IL-21, IL-22, IL-6) and tumour necrosis factor-alpha (TNF-α) and hen...Continue Reading

References

Jan 25, 2000·American Journal of Physiology. Endocrinology and Metabolism·W TavaresP L Brubaker
Jun 4, 2002·Nature Medicine·Markus F NeurathLaurie H Glimcher
Oct 3, 2002·Nature Reviews. Immunology·Qiutang Li, Inder M Verma
Feb 25, 2006·Cell·Shizuo AkiraOsamu Takeuchi
May 25, 2006·Neuroscience Research·Takashi IwaiJun-Ichiro Oka
Oct 13, 2006·Current Opinion in Gastroenterology·F Pallone, G Monteleone
Mar 3, 2007·The Journal of Clinical Investigation·Warren StroberPeter Mannon
Mar 3, 2007·Pediatric Surgery International·Masahiro ChibaYoshinori Hirai
May 16, 2008·Journal of Internal Medicine·I AtreyaM F Neurath
Feb 27, 2010·Inflammatory Bowel Diseases·Roger YazbeckCatherine A Abbott
Aug 23, 2011·Pharmacological Reports : PR·Anand B Pithadia, Sunita Jain
May 9, 2012·Regulatory Peptides·G W MoranJ T McLaughlin
Nov 20, 2012·Annual Review of Pathology·Casey T WeaverJay K Kolls
Mar 26, 2013·Peptides·Chinmay S MaratheMichael Horowitz
Apr 30, 2013·Expert Opinion on Drug Safety·Andre Scheen
Jul 3, 2013·International Journal of Obesity : Journal of the International Association for the Study of Obesity·T A WaddenUNKNOWN NN8022-1923 Investigators
Apr 22, 2014·Expert Opinion on Drug Metabolism & Toxicology·Theodosios D FilippatosMoses S Elisaf
Aug 15, 2014·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Shanshan XieDianfeng Liu
Feb 7, 2015·American Journal of Physiology. Renal Physiology·Yoshiki HigashijimaMasaomi Nangaku
May 24, 2015·Current Opinion in Clinical Nutrition and Metabolic Care·Tamara Zietek, Hannelore Daniel
May 28, 2015·American Journal of Physiology. Endocrinology and Metabolism·Takanori ShinjoTomoichiro Asano
Aug 20, 2016·Inflammatory Bowel Diseases·Claus H Bang-BerthelsenKlaus S Frederiksen
Aug 25, 2016·Nanomedicine : Nanotechnology, Biology, and Medicine·Arivarasu N AnbazhaganPradeep K Dudeja
Mar 7, 2017·Immune Network·Duk Hwan Kim, Jae Hee Cheon
Jul 21, 2017·The Journal of Pharmacology and Experimental Therapeutics·Maciej SalagaJakub Fichna
Feb 1, 2019·The Annals of Pharmacotherapy·Joshua A RadelSachin A Shah
Jul 11, 2019·Neural Regeneration Research·Antonella Amato, Flavia Mulè
Jul 31, 2019·Naunyn-Schmiedeberg's Archives of Pharmacology·Hubert ZatorskiJakub Fichna

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

© 2022 Meta ULC. All rights reserved